Forsinkede kurser. Sist oppdatert: tirsdag 18. juni  

20/02-2019 12:01:17: (NANO) Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2018 Results Presentation and Webcast

Oslo, Norway, 20 February 2019

Nordic Nanovector ASA (OSE: NANO) announces that it will report its fourth
quarter and full year 2018 results on Wednesday, 27 February 2019.

A presentation by Nordic Nanovector's senior management team will take place at
8:30 am CET at:

Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: AKER

The presentation will be recorded as a webcast and will be available at
www.nordicnanovector.com in the section: Investors & Media

The results report and the presentation will be available at
www.nordicnanovector.com in the section: Investors & Media/Reports and
Presentation/Interim Reports/2018 from 7:00 am CET the same day.

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email:  nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37
-targeting antibody-radionuclide-conjugate designed to advance the treatment of
non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet
medical need,

representing a growing market forecast to be worth nearly USD 29 billion by
2026. Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and
5-12 of the Securities Trading Ac

Ekstern link: https://newsweb.oslobors.no/message/470098

Nyheten er levert av OBI.